Literature DB >> 8004758

Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.

C D Evans1, S E Mirski, M K Danks, S P Cole.   

Abstract

We have previously shown that the doxorubicin-selected multidrug-resistant small-cell lung-cancer cell line H69AR is resistant to VP-16-induced single-strand DNA breaks as compared with its parental H69 cell line. Levels of immunoreactive topoisomerase II alpha are also reduced in H69AR cells. In the present study, we found that cleaved complex formation in the presence of VP-16 was decreased in H69AR cells as compared with H69 cells. In addition, the resistant cells contained lower levels of both topoisomerase II alpha and topoisomerase II beta protein and mRNA. However, these changes were not accompanied by a decrease in the P4-unknotting (strand-passing) activity of 0.67 M NaCl nuclear extracts of H69AR cells, nor was there any difference in VP-16 inhibition of unknotting activity in the H69 and H69AR nuclear extracts. These data suggest that reduced levels of topoisomerase II alpha and II beta may contribute to the resistance of H69AR cells to VP-16 and other drugs that target these isoenzymes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8004758     DOI: 10.1007/BF00685084

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  46 in total

Review 1.  Catalytic function of DNA topoisomerase II.

Authors:  N Osheroff; E L Zechiedrich; K C Gale
Journal:  Bioessays       Date:  1991-06       Impact factor: 4.345

2.  Evidence that a protein kinase enhances amsacrine mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei.

Authors:  S J Darkin-Rattray; R K Ralph
Journal:  Biochim Biophys Acta       Date:  1991-02-16

3.  Systemic therapy for small-cell lung cancer: old themes replayed, new ones awaited.

Authors:  J Viallet; D C Ihde
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

4.  Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

Authors:  M K Danks; C A Schmidt; M C Cirtain; D P Suttle; W T Beck
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

5.  Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases.

Authors:  L F Liu; J L Davis; R Calendar
Journal:  Nucleic Acids Res       Date:  1981-08-25       Impact factor: 16.971

6.  Biochemical characterization of topoisomerase I purified from avian erythrocytes.

Authors:  D K Trask; M T Muller
Journal:  Nucleic Acids Res       Date:  1983-05-11       Impact factor: 16.971

7.  Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

Authors:  B Y Bugg; M K Danks; W T Beck; D P Suttle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

8.  Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 9.  Regulation of topoisomerase II by phosphorylation: a role for casein kinase II.

Authors:  M E Cardenas; S M Gasser
Journal:  J Cell Sci       Date:  1993-02       Impact factor: 5.285

10.  Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24.

Authors:  J R Jenkins; P Ayton; T Jones; S L Davies; D L Simmons; A L Harris; D Sheer; I D Hickson
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

View more
  2 in total

1.  Topoisomerase II alpha mRNA and tumour cell proliferation in non-Hodgkin's lymphoma.

Authors:  A Lohri; J Reuter; F Gudat; R Herrmann
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

Review 2.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.